| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Attovia | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $255.85M | Series C | 4/15/2025 | $90M | $368.16M | $12.77 | Deep Track Capital, Vida Ventures, Sanofi Ventures, Mirae Asset Capital Life Science, Frazier Life Sciences, venBio, Goldman Sachs, Nextech Ventures, Cormorant Asset Management, EcoR1 Capital, Marshall Wace, Illumina Ventures | ||||
 | BlossomHill Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $257.15M | Series B | 2/29/2024 | $184.15M | $400.87M | $17.63 | Colt Ventures, Cormorant Asset Management, OrbiMed, Vivo Capital, Hercules BioVentures Partners, Plaisance Capital Management, H&D Asset Management, Brahma Capital, Primer Ventures | ||||
 | Boundless Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $756.15M | Series C | 5/16/2023 | $100M | $273.76M | $0.70 | Bayer, RA Capital Management, Sectoral Asset Management, Piper Heartland, Healthcare Capital | ||||
 | Iambic Therapeutics | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $395.29M | Series B-4 | 4/1/2026 | $32.77M | $671.11M | $3.26 | Undisclosed Investors | ||||
 | Latigo Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $287.9M | Series B | 3/17/2025 | $150M | $525.73M | $1.57 | Blue Owl Capital, Deep Track Capital, Access Biotechnology, Qatar Investment Authority, Cormorant Asset Management, Sanofi Ventures, Rock Springs Capital, UPMC Enterprises, Kern Capital, Westlake Village BioPartners, Foresite Capital, 5AM Ventures, Alexandria Venture Investments | ||||
 | Upstream Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $800M | Series B | 6/8/2023 | $200M | $676.16M | $17.00 | Enavate Sciences, Venrock Healthcare Capital Partners, Bain Capital Life Sciences, Wellington Management, OrbiMed, Access Biotechnology, Decheng Capital, Altshuler Shaham Provident Funds Ltd., TCG X, HBM Healthcare Investments, Omega Funds, Samsara BioCapital | ||||
 | Aardvark Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $129.13M | Series C | 5/9/2024 | $85M | $267.58M | $1.77 | Decheng Capital, Cormorant Asset Management, Surveyor Capital, SymBiosis, Tetragon Financial Group, Walleye Capital, Laurion Capital Management, LG Technology Ventures, Cantor Ventures, Silver Arc Private Capital, Prader-Willi Syndrome Association, Vickers Venture Partners, Foundation for Prader-Willi Research | ||||
 | Lyell | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.04B | Series C | 3/5/2020 | $493M | $2.5B | $11.49 | ARCH Venture Partners, Foresite Capital, Milky Way Investments | ||||
 | Caris Life Sciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Evommune | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $268.46M | Series C | 10/31/2024 | $115.5M | $346.35M | $1.59 | RA Capital Management, Sectoral Asset Management, B Capital, Marshall Wace, Avego Bioscience Capital, Longwood Fund, RTW Investments, ADAR1 Capital Management, NEXTBio Capital, Beiersdorf Venture Capital, FemHealth Ventures, Allostery Investments LP, Pivotal bioVenture Partners, EQT Life Sciences, Andera Partners, Amplitude Ventures, SymBiosis, Verition Fund Management | ||||
 | Medline Industries | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | 4D Molecular Therapeutics (4DMT) | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | 908 Devices | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Beta Bionics | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | CG Oncology | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $510.76M | Series F | 8/2/2023 | $105.02M | $615.24M | $1.29 | Foresite Capital, TCGX, Avidity Partners, BVF Partners, Janus Henderson Investors, Acorn Bioventures, Ally Bridge Group, Decheng Capital, Longitude Capital, Malin Corporatoin, RA Capital Management | ||||
 | Kardigan | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $607.17M | Series B-1 | 10/14/2025 | $80.78M | $1.6B | $21.37 | Fidelity, T. Rowe Price, ARCH Venture Partners, Sequoia Heritage | ||||
 | Maze Therapeutics | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $503.77M | Series D | 12/3/2024 | $76.4M | $552.39M | $1.38 | Frazier Life Sciences, Deep Track Capital, Janus Henderson Investors, Logos Capital | ||||
 | PMV Pharma | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Sionna Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $331.32M | Series C | 3/6/2024 | $181.86M | $523.7M | $9.76 | Enavate Sciences, Viking Global Investors, Perceptive Advisors, RA Capital, TPG, Atlas Venture, Cystic Fibrosis Foundation, T. Rowe Price, Qatar Investment Authority, OrbiMed | ||||
 | Treace Medical Concepts | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | XtalPi | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Alto Neuroscience | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $253.17M | Series C | 11/21/2023 | $50.31M | $235.65M | $4.71 | InVivium Capital, Franklin Templeton, Point72, Eli Lilly and Company, Alexandria Venture Investments, Alpha Wave Ventures, Lightswitch Capital, Alkeon Capital, WhatIf Ventures, Windham Venture Partners | ||||
 | American Well | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $674M | Series C | 5/20/2020 | $617M | $1.03B | $45.00 | InVenture Partners, Anthem, Teva Pharmaceutical Industries, Allianz X, Philips, Martin Ventures, Hanaco Venture Capital, Cito Ventures, ADIP, Echo Health Ventures, McKesson Ventures, Waterline Ventures, Westway Capital, SV Health Investors | ||||
 | Candel Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||